{
    "id": 3235,
    "fullName": "SMO T640A",
    "impact": "missense",
    "proteinEffect": "no effect - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SMO T640A lies within the C-terminal cytoplasmic tail of the Smo protein (PMID: 25801792). T640A has activity similar to wild-type Smo in cultured cells (PMID: 17287906, PMID: 25801792) and therefore, is predicted to have no effect on Smo protein function.",
            "references": [
                {
                    "id": 13490,
                    "pubMedId": 25801792,
                    "title": "Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25801792"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 5529,
                    "pubMedId": 17287906,
                    "title": "Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17287906"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "T640A",
    "createDate": "02/19/2015",
    "updateDate": "09/24/2019",
    "referenceTranscriptCoordinates": {
        "id": 123236,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129211752A>G",
        "cDna": "c.1918A>G",
        "protein": "p.T640A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15687,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO T640A resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).",
            "molecularProfile": {
                "id": 3056,
                "profileName": "SMO T640A"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13490,
                    "pubMedId": 25801792,
                    "title": "Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25801792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3056,
            "profileName": "SMO T640A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123236,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129211752A>G",
            "cDna": "c.1918A>G",
            "protein": "p.T640A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}